Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is trading near its 52-week high, with investors weighing meaningful pipeline and commercial-product news against a setback for a lung-cancer candidate. The stock’s valuation is elevated, making progress in replacing future Keytruda revenue especially important.

• Positive Sentiment: Merck agreed to license global rights to SciBrunch Therapeutics’ experimental oral KRAS G12D inhibitor, SPR2015. The deal includes a $400 million upfront payment and could total up to $2.13 billion, giving Merck access to a potentially important oncology target and strengthening its long-term pipeline. However, the drug remains preclinical, so commercial benefits are distant and uncertain. Merck licenses SciBrunch cancer drug deal worth up to $2.13 billion
• Positive Sentiment: The FDA expanded Welireg’s label to include a third indication for advanced kidney cancer. The broader approval could support additional adoption and sales growth for the oncology drug. FDA expands Merck's Welireg label
• Positive Sentiment: CAPVAXIVE was added to Ontario’s publicly funded adult pneumococcal immunization program, improving access among eligible older adults and potentially expanding vaccine demand in Canada. CAPVAXIVE included in Ontario's immunization program
• Neutral Sentiment: Merck and Mission Bio will present research using Mission Bio’s single-cell platform at a clinical biomarkers conference. The update may support research visibility but is unlikely to materially affect near-term revenue. Mission Bio showcases Tapestri platform
• Negative Sentiment: Merck and Daiichi Sankyo withdrew their FDA filing for ifinatamab deruxtecan after regulators indicated the available data would not support accelerated approval. The decision removes a potential near-term lung-cancer opportunity and a competitive advantage, although late-stage studies are continuing. Merck and Daiichi end plans for speedy lung-cancer approval